Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
An in Vitro Evaluation of Anti-Aging Effect of Guluronic Acid (G2013) Based on Enzymatic Oxidative Stress Gene Expression Using Healthy Individuals Pbmcs Publisher Pubmed



Taeb M1 ; Mortazavijahromi SS2 ; Jafarzadeh A1 ; Mirzaei MR3 ; Mirshafiey A4
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Immunology, School of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran
  2. 2. Department of Cellular and Molecular Biology, Kish International Campus, University of Tehran, Kish, Iran
  3. 3. Molecular Medicine Research Center, Rafsanjan University of Medical Sciences, Box: 771664-8798, Rafsanjan, Iran
  4. 4. Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Box: 14155-6446, Tehran, Iran

Source: Biomedicine and Pharmacotherapy Published:2017


Abstract

Background Aging is usually associated with increased levels of oxidants, and may result in damages caused by oxidative stress. There is a direct relationship between aging and increased incidence of inflammatory diseases. The present research intended to study the anti-aging and anti-inflammatory effects of the drug G2013 (guluronic acid) at low and high doses on the genes expression of a number of enzymes involved in oxidative stress (including SOD2, GPX1, CAT, GST, iNOS, and MPO) in peripheral blood mononuclear cells (PBMCs) of healthy individuals under in vitro conditions. Methods Venous blood samples were taken from 20 healthy individuals, the PBMCs were isolated and their RNAs extracted and their cDNAs were synthesized, and the genes expression levels were measured using the qRT-PCR technique. Results Our results indicated that this drug could, at both low and high doses, significantly reduce the expression of the genes for SOD2, GPX1, CAT, and GST compared to the LPS group (p < 0.0001). Moreover, it was noticed that the drug is able to significantly reduce gene expression levels at the high dose and at both doses (low and high), for iNOS and MPO compared to the LPS group (p < 0.0001), respectively. Conclusions The present research showed that G2013, as a novel NSAID drug with immunomodulatory properties, could modulate the expression levels of the genes for SOD2, GPX1, CAT, GST, iNOS, and MPO, to the level of healthy gene expression, and possibly it might reduce the pathological process of aging and age-related inflammatory diseases. © 2017
Related Docs
View other Related Docs
1. Effect of Β-D-Mannuronic Acid (M2000) on Oxidative Stress Enzymes’ Gene Using Healthy Donor Peripheral Blood Mononuclear Cells for Evaluating the Anti-Aging Property, Current Drug Discovery Technologies (2019)
2. Anti-Aging Property of G2013 Molecule As a Novel Immunosuppressive Agent on Enzymatic and Non-Enzymatic Oxidative Stress Determinants in Rat Model, Current Drug Discovery Technologies (2016)
3. The Immunomodulatory Role of G2013 (Α-L-Guluronic Acid) on the Expression of Tlr2 and Tlr4 in Ht29 Cell Line, Current Drug Discovery Technologies (2019)
4. The Open, Randomized, Positive Control Clinical Trial of Guluronic Acid (G2013) on Sars-Cov-2 Patients, Current Drug Discovery Technologies (2023)
5. Immunomodulatory Effect of G2013 (Α-L-Guluronic Acid) on the Tlr2 and Tlr4 in Human Mononuclear Cells, Current Drug Discovery Technologies (2018)
6. Evaluation of the Effect of Α-L-Guluronic Acid (G2013) on Cox-1, Cox-2 Activity and Gene Expression for Introducing This Drug As a Novel Nsaid With Immunomodulatory Property, Recent Patents on Inflammation and Allergy Drug Discovery (2018)
7. Preclinical and Pharmacotoxicology Evaluation of Α-L-Guluronic Acid (G2013) As a Non-Steroidal Anti-Inflammatory Drug With Immunomodulatory Property, Immunopharmacology and Immunotoxicology (2017)
8. Anti-Aging Effects of M2000 (Β-D-Mannuronic Acid) As a Novel Immunosuppressive Drug on the Enzymatic and Non-Enzymatic Oxidative Stress Parameters in an Experimental Model, Journal of Basic and Clinical Physiology and Pharmacology (2017)
Experts (# of related papers)
View all Related Experts
Laleh Sharifi (4)
Noushin Rastkari (3)
Other Related Docs
9. Effects of Guluronic Acid (G2013) on Ship1, Socs1 Induction and Related Molecules in Tlr4 Signaling Pathway, International Immunopharmacology (2018)
10. Antagonistic Property of G2013 (Α-L-Guluronic Acid) on Gene Expression of Myd88, Tollip, and Nf-Κb in Hek293 Tlr2 and Hek293 Tlr4, Endocrine# Metabolic and Immune Disorders - Drug Targets (2019)
11. Assessment of Immunological Profile in Ankylosing Spondylitis Patients Following a Clinical Trial With Guluronic Acid (G2013), As a New Nsaid With Immunomodulatory Properties, Immunologic Research (2019)
12. Effect of Guluronic Acid (G2013), As a New Anti-Inflammatory Drug on Gene Expression of Pro-Inflammatory and Anti-Inflammatory Cytokines and Their Transcription Factors in Rheumatoid Arthritis Patients, Iranian Journal of Allergy# Asthma and Immunology (2019)
13. Anti-Diabetic and Angio-Protective Effect of Guluronic Acid (G2013) As a New Nonsteroidal Anti-Inflammatory Drug in the Experimental Model of Diabetes, Endocrine# Metabolic and Immune Disorders - Drug Targets (2020)
14. The Evaluation of Safety Property and Apoptotic Efficacy of Α-L-Guluronic Acid (G2013), As a Novel Nsaid, Under in Vitro Examination on L929 and Hepatocellular Carcinoma Cell Lines, Recent Advances in Inflammation and Allergy Drug Discovery (2021)
15. Anti‐Inflammatory and Anti‐Tumor Effects of Α-L-Guluronic Acid (G2013) on Cancer-Related Inflammation in a Murine Breast Cancer Model, Biomedicine and Pharmacotherapy (2018)
16. Efficacy and Safety of G2013 As a Novel Immunosuppressive Agent on Differentiation, Maturation and Function of Human Dendritic Cells, Iranian Journal of Public Health (2017)
17. G2013 Modulates Tlr4 Signaling Pathway in Irak-1 and Tarf-6 Dependent and Mir-146A Independent Manner, Cellular and Molecular Biology (2016)
18. The Potent Suppressive Effect of Β-D-Mannuronic Acid (M2000) on Molecular Expression of the Tlr/Nf-Kb Signaling Pathway in Ankylosing Spondylitis Patients, International Immunopharmacology (2017)
19. The Safety and Efficacy of Guluronic Acid (G2013) in Ankylosing Spondylitis: A Randomized Controlled Parallel Clinical Trial, Pharmacological Reports (2019)
20. Pivotal Cytokines and Their Transcription Factors Are the Targets of Guluronic Acid (G2013) for Inhibiting the Immunopathogenesis Process of Multiple Sclerosis, Drug Development Research (2020)
21. Higher Dietary Total Antioxidant Capacity Is Inversely Related to Prediabetes: A Case-Control Study, Nutrition (2018)
22. Evaluation of G2013 (Α-L-Guluronic Acid) Efficacy on Pc-3 Cells Through Inhibiting the Expression of Inflammatory Factors, Clinical and Experimental Pharmacology and Physiology (2022)
23. Evaluation of the Acute and 28-Day Sub-Acute Intravenous Toxicity of Α-L-Guluronic Acid (Alg; G2013) in Mice, Drug and Chemical Toxicology (2022)
24. Inhibitory Effect of G2013 Molecule As a Novel Immunomodulatory Agent, on Mir-155 Gene Expression in Hek-Blue Htlr4 Cell Line, European Journal of Inflammation (2016)
25. Evaluation of the Oral Administration of Α-L-Guluronic Acid on Cox-1 and Cox-2 Gene Expression Profile in Ankylosing Spondylitis Patients, Drug Development Research (2021)
26. Modification of Sexual Hormones in Rheumatoid Arthritis Patients by M2000 (Β-D-Mannuronic Acid) As a Novel Nsaid With Immunosuppressive Property, Endocrine# Metabolic and Immune Disorders - Drug Targets (2018)
27. The Role of M2000 As an Anti-Inflammatory Agent in Toll-Like Receptor 2/Microrna-155 Pathway, Avicenna Journal of Medical Biotechnology (2017)
28. Pharmacological Effects of Β-D-Mannuronic Acid (M2000) on Mir-146A, Irak1, Traf6 and Nf-Κb Gene Expression, As Target Molecules in Inflammatory Reactions, Pharmacological Reports (2017)
29. Introduction of Β-D-Mannuronic Acid (M2000) As a Novel Nsaid With Immunosuppressive Property Based on Cox-1/Cox-2 Activity and Gene Expression, Pharmacological Reports (2017)
30. Preclinical Assessment of Β - D -Mannuronic Acid (M2000) As a Non-Steroidal Anti-Inflammatory Drug, Immunopharmacology and Immunotoxicology (2015)
31. Effects of Guluronic Acid, As a New Nsaid With Immunomodulatory Properties on Il-17, Rorγt, Il-4 and Gata-3 Gene Expression in Rheumatoid Arthritis Patients, Immunopharmacology and Immunotoxicology (2020)
32. The Application of G2013 (Α-L-Guluronic Acid) As an Anti-Inflammatory Drug Candidate in Treatment of Disease, Journal of Isfahan Medical School (2021)
33. The Effects of Guluronic Acid (G2013), a New Emerging Treatment, on Inflammatory Factors in Nonalcoholic Steatohepatitis Patients Under in Vitro Conditions, Immunopharmacology and Immunotoxicology (2021)
34. Effects of Guluronic Acid (G2013) on Gene Expression of Tlr2, Tlr4, Myd88, Tnf-Α and Cd52 in Multiple Sclerosis Under in Vitro Conditions, Immunopharmacology and Immunotoxicology (2019)
35. A Randomized Clinical Trial for the Assessment of the Efficacy and Safety of Guluronic Acid (G2013) in Patients With Rheumatoid Arthritis, Immunopharmacology and Immunotoxicology (2019)
36. The Inhibitory Role of M2000 (Β-D-Mannuronic Acid) on Expression of Toll-Like Receptor 2 and 4 in Ht29 Cell Line, Recent Patents on Inflammation and Allergy Drug Discovery (2019)
37. 17Β-Estradiol Stimulates Generation of Reactive Species Oxygen and Nitric Oxide in Ovarian Adenocarcinoma Cells (Ovcar 3), International Journal of Cancer Management (2015)